Abstract
With the beginning of the 21st century, a new and exciting era for cancer therapy has begun with the appearance of molecular targeted drugs. Numerous drugs for chemotherapy have been discovered following careful screening of natural and synthetic components. After screening, candidate chemotherapy drugs are examined to determine if they have sufficiently cytotoxic to function as an anti-tumor therapeutic. However, the development of molecular targeted drugs is based on more logical methodologies. First, the target is determined then a search is conducted for molecules able to inhibit the target molecule. Some molecular targeting drugs, such as Glivec (Imatinib, STI571), have shown amazing effects when compared to currently used chemotherapy drugs, whereas few others have completely failed to inhibit tumor development in clinical trials. Thus, an efficient method for finding effective molecular targeted drugs is needed. An important question is whether the target molecule is responsible for tumor growth or metastasis. In addition, the clinical administration schedule must be suitable for the component used. The drugs will not be completely successful in clinical trials if any of the key points are overlooked. Translational studies are necessary for a complete evaluation of molecular targeted drugs and, based on the results observed in clinical applications, the testers must return to their basic laboratory if necessary and improve the drugs for more advanced therapy. In this review we discuss on the current and future status of molecular target drugs.
Keywords: Cancer, molecular targeted therapy, antibody, small molecule, personalized medicine, proof of principle, translational research, review
Current Cancer Drug Targets
Title: Current Status and Future of Target-Based Therapeutics
Volume: 7 Issue: 3
Author(s): Ryoko Suzuki, Parijatha Rao and Shiro Sasaguri
Affiliation:
Keywords: Cancer, molecular targeted therapy, antibody, small molecule, personalized medicine, proof of principle, translational research, review
Abstract: With the beginning of the 21st century, a new and exciting era for cancer therapy has begun with the appearance of molecular targeted drugs. Numerous drugs for chemotherapy have been discovered following careful screening of natural and synthetic components. After screening, candidate chemotherapy drugs are examined to determine if they have sufficiently cytotoxic to function as an anti-tumor therapeutic. However, the development of molecular targeted drugs is based on more logical methodologies. First, the target is determined then a search is conducted for molecules able to inhibit the target molecule. Some molecular targeting drugs, such as Glivec (Imatinib, STI571), have shown amazing effects when compared to currently used chemotherapy drugs, whereas few others have completely failed to inhibit tumor development in clinical trials. Thus, an efficient method for finding effective molecular targeted drugs is needed. An important question is whether the target molecule is responsible for tumor growth or metastasis. In addition, the clinical administration schedule must be suitable for the component used. The drugs will not be completely successful in clinical trials if any of the key points are overlooked. Translational studies are necessary for a complete evaluation of molecular targeted drugs and, based on the results observed in clinical applications, the testers must return to their basic laboratory if necessary and improve the drugs for more advanced therapy. In this review we discuss on the current and future status of molecular target drugs.
Export Options
About this article
Cite this article as:
Suzuki Ryoko, Rao Parijatha and Sasaguri Shiro, Current Status and Future of Target-Based Therapeutics, Current Cancer Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/156800907780618275
DOI https://dx.doi.org/10.2174/156800907780618275 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation
Current Pharmaceutical Biotechnology Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Amino Acid Derived Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs
Current Topics in Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research